- Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
- Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
- Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
- Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
- Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
More ▼
Key statistics
As of last trade Crinetics Pharmaceuticals Inc (6Z4:FRA) traded at 40.80, -3.32% below its 52-week high of 42.20, set on Mar 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 40.80 |
---|---|
High | 40.80 |
Low | 40.80 |
Bid | 41.00 |
Offer | 41.40 |
Previous close | 40.00 |
Average volume | 101.56 |
---|---|
Shares outstanding | 77.93m |
Free float | 74.96m |
P/E (TTM) | -- |
Market cap | 3.46bn USD |
EPS (TTM) | -3.70 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 07:00 BST.
More ▼